Immuno-Oncology Archives

FDA approves combination therapy of tremelimumab, durvalumab, and platinum-based chemotherapy for metastatic NSCLC

The U.S. Food and Drug Administration (FDA) have approved tremelimumab in combination with durvalumab and platinum-based chemotherapy for metastatic non-small…

Worse outcomes for immunosuppressed patients with cancer and COVID-19 treated with immunotherapy

A report published in JAMA Oncology suggests that cancer patients with baseline immunosuppression and COVID-19 experience worse outcomes and an…

Clinical breakthroughs in immunotherapy from SITC 2022

VJOncology are excited to highlight the latest in immuno-oncology from the 37th Annual Meeting of the Society for Immunotherapy in…

First-line maintenance with olaparib monotherapy and in combination bevacizumab increases survival in advanced ovarian cancer

Over 75% of patients with ovarian cancer are diagnosed at an advanced stage, as early-stage disease is usually asymptomatic.1,2 The…

TROPiCS-02: Overall survival benefit of sacituzumab govitecan in HR+/HER2- metastatic breast cancer

Antibody-drug conjugates (ADCs) are an emerging class of anticancer drugs consisting of a monoclonal antibody linked to a cytotoxic chemotherapy…

New research elucidates how air pollution causes lung cancer in never-smokers

Research presented at the European Society of Medical Oncology (ESMO) Congress 2022 has uncovered a non-mutagenic mechanism by which air…

EV-103 Cohort K: Promising data for first-line combination therapy of enfortumab vedotin plus pembrolizumab for patients with urothelial carcinoma

EV-103 (NCT03288545) is a multicohort study investigating the use of the antibody-drug conjugate, enfortumab vedotin, alone or in combination with…

Top picks from WCLC 2022: NADIM II, IMpower010, CALGB 140503, YESS

VJOncology are thrilled to present our top picks from the the IASLC 2022 World Conference on Lung Cancer (WCLC) congress!

MOUNTAINEER: Tucatinib plus trastuzumab demonstrates good efficacy for the treatment of HER2-positive metastatic colorectal cancer

In the U.S., colorectal cancer (CRC) is the third leading cause of cancer-related deaths and is expected to lead to…

Highlights from ASCO 2022

VJOncology are excited to present our top picks from the American Society of Clinical Oncology (ASCO) 2022 Annual Meeting!

Top 5 picks from ASCO GU 2022

Catch the latest updates in GU with VJOncology from the American Society of Clinical Oncology (ASCO) Genitourinary Cancer Symposium 2022!

Highlights from ASCO GI 2022

VJOncology brings you highlights in GI cancer from this year’s virtual American Society of Clinical Oncology (ASCO) Gastrointestinal Cancer Symposium!

Top picks from SABCS 2021

The San Antonio Breast Cancer Symposium (SABCS) took place on the 7-10 December 2021, both virtually and in-person. We heard…

FDA grants priority review for fixed-dose relatlimab plus nivolumab in melanoma based on RELATIVITY-047

The U.S Food and Drug Administration (FDA) has granted priority review for the fixed-dose combination of relatlimab, a LAG-3 targeting…

Highlights from ESMO 2021

Check out our top picks from ESMO 2021!

Top 5 in lung from ASCO 2021

Highlights from ASCO 2021 in lung cancer! Learn more about the major clinical trials reported at this year’s meeting.

features: Immuno-Oncology